Bengtsson et al., 2017 - Google Patents
Role of interferons in SLEBengtsson et al., 2017
- Document ID
- 8300279581255120824
- Author
- Bengtsson A
- Rönnblom L
- Publication year
- Publication venue
- Best practice & research Clinical rheumatology
External Links
Snippet
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects many different organ systems, with excessive production of type I interferons (IFNs) and autoantibodies against nucleic acids as hallmarks. Activation of the type I IFN system in …
- 102000014150 Interferons 0 title abstract description 164
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bengtsson et al. | Role of interferons in SLE | |
| Crow et al. | Type I interferons in host defence and inflammatory diseases | |
| Willemsen et al. | TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis | |
| Crow et al. | Type I interferons in autoimmune disease | |
| Rönnblom et al. | The type I interferon system in the development of lupus | |
| Lee et al. | Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children | |
| Wang et al. | Inhibition of AIM 2 inflammasome activation by a novel transcript isoform of IFI 16 | |
| Hemann et al. | Interferon lambda genetics and biology in regulation of viral control | |
| Psarras et al. | Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy | |
| Eloranta et al. | Cause and consequences of the activated type I interferon system in SLE | |
| Rönnblom | The type I interferon system in the etiopathogenesis of autoimmune diseases | |
| Hagberg et al. | Systemic lupus erythematosus–a disease with a dysregulated type I interferon system | |
| Crow et al. | Targeting of type I interferon in systemic autoimmune diseases | |
| Zimmermann et al. | IFNα enhances the production of IL-6 by human neutrophils activated via TLR8 | |
| Elkon et al. | Type I interferon and systemic lupus erythematosus | |
| Chapgier et al. | A partial form of recessive STAT1 deficiency in humans | |
| Fuchs et al. | Tyrosine kinase 2 is not limiting human antiviral type III interferon responses | |
| Aarreberg et al. | Interleukin-1β signaling in dendritic cells induces antiviral interferon responses | |
| Travar et al. | Type I, II, and III interferons: regulating immunity to Mycobacterium tuberculosis infection | |
| Tomasello et al. | Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types | |
| Wang et al. | dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity | |
| Paludan | Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes | |
| Dalskov et al. | Viral recognition and the antiviral interferon response | |
| Jin et al. | The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus | |
| Menendez et al. | p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus |